Peptides DB
Research-centric peptide and protocol reference hub

KLOW Protocol record · updated 20h ago

Healing & recoveryMetabolic & appetiteGrade D · emergingResearch use only
Evidence for its componentsCompare
What is KLOW Protocol used for?

KLOW is a four-peptide compounded blend (typically KPV, LL-37, GHK, and Wolverine-style healing peptides) studied informally for combined regenerative and metabolic effects.

Primarily researched for · Healing & recovery

Development stage

where KLOW Protocol sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.

Identity
NameKLOW Protocol
Chain length—
Molecular weight—
Formula—
Structure type—
ClassWeight Loss
Research levelLimited Research
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies0
Human / animal / cellular0 / 0 / 0
Highest trial phase—
Years covered—
Latest study—
Publication history
No publication years on file
——
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

no studies of its own · newest 12 of 58 from its componentsOpen in the library →
No direct evidence

No study in this library has tested this combination directly. The papers below examined its components individually — each row is labelled with the single compound that study looked at.

Evidence for one component is not evidence for the combination. Nothing below measured what happens when these compounds are used together.

StudyTypeYearSummary depth
Superconducting 2D cuprate with a single CuO(2) plane.
FindingApproximately 10% reduction in optimal superconducting transition temperature.
—2026Partial text0.50
Ultralong sheathed single-metal-atom chains synthesized under high pressure.
TakeawayNot reported in abstract.
—2026Title only0.10
Ultrasensitive low-density lipoprotein monitoring in early cardiovascular risk assessment via Cu-MOF-Apt/MoS₂ fluorescent nanosensor.
Findingultra-low detection limit (0.0789 ng/mL)
In vitro2026Full text read0.70
pH and temperature-dependent structural and functional stability of hemocyanin from Tachypleus gigas: A multispectroscopic, phenoloxidase activity and computational study.
Finding80% phenoloxidase activity up to 70 °C.
In vitro2026Full text read0.70
Room-temperature multiferroicity in all-van der Waals heterostructures.
TakeawayNot reported in abstract.
—2026Title only0.10
Construction and validation of a prediction model for graft failure in pediatric liver transplant recipients based on the APRI-ALBI score: a retrospective study of 289 cases.
FindingAUC of 0.706 for the nomogram predicting graft failure.
Human2026Full text read0.80
Causes and timing of death in extremely premature infants from 2000 through 2011.
Finding275 deaths per 1000 live births from 2000 through 2003, 95% CI 264 to 285.
Human2015Full text read0.90
Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia.
FindingSurvival without moderate or severe bronchopulmonary dysplasia at 36 weeks was 16.6% in the hydrocortisone group and 13.2% in the placebo group.
Human2022Full text read0.90
Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns.
FindingIncidence of death or neurodevelopmental impairment was 52.5% in the erythropoietin group and 49.5% in the placebo group, relative risk 1.03, 95% CI 0.86 to 1.24, P=0.74.
Human2022Full text read0.90
Maternal potassium-magnesium sulfate supplementation in low-protein diets improves performance and health of sows and suckling piglets.
FindingWeaning-to-estrus interval decreased linearly with increasing PMS supplementation, p=0.022.
Animal2026Full text read0.80
Dissecting the evolutionary forces shaping codon usage bias in SFTSV from eastern China: Insights from a previously underrepresented region.
FindingNatural selection accounted for 52.8-91.4% of codon usage bias.
In vitro2026Full text read0.70
Metabolomic analysis of follicular fluid in women with unexplained infertility.
FindingSignificantly reduced levels of follicular 25-hydroxyvitamin D despite uniform oral supplementation.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching KLOW Protocol will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much KLOW Protocol is discussed should be drawn from it.